Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Caladrius Biosciences Inc Market Cap
From what 2 stock analysts predict, the share price for Caladrius Biosciences Inc (CLBS) might decrease by 100% in the next year. This is based on a 12-month average estimation for CLBS. Price targets go from $ to $. The majority of stock analysts believe CLBS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Caladrius Biosciences Inc has a total of 2 Wall St Analyst ratings. There are 2 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Caladrius Biosciences Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of CLBS.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Joseph Pantginis HC Wainwright & Co. | Buy | $6 | Maintains | Mar 23, 2022 |
| Raja Kumaraguru Brookline Capital | Buy | $10 | Maintains | Mar 3, 2021 |
WBB Securities | Speculative Buy | Initiates | May 14, 2019 | |
| Keay Nakae Chardan Capital | Buy | $7 | Maintains | Mar 23, 2018 |
H.C. Wainwright | Buy | Maintains | Mar 7, 2018 | |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $12 | Maintains | Mar 7, 2018 |
Chardan Capital | Buy | Initiates | Aug 23, 2016 | |
H.C. Wainwright | Buy | Upgrade | Apr 29, 2016 | |
H.C. Wainwright | Neutral | Downgrade | Jan 8, 2016 | |
Benchmark | Hold | $1 | Maintains | Jan 8, 2016 |
Maxim Group | Hold | Downgrade | Jan 7, 2016 | |
Benchmark | Downgrade | Aug 7, 2015 |
When did it IPO
1999
Staff Count
0
Country
United States
Sector/Industry
/
CEO
Market Cap
$10.7M
In 2023, CLBS generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CLBS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 15 Sep 2022
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The company will begin trading on The Nasdaq Capital Market with the ticker symbol "LSTA."
Why It Matters - Trading on Nasdaq under ticker "LSTA" enhances visibility and credibility, potentially attracting more investors and increasing liquidity, which can positively impact share price.
Wed, 14 Sep 2022
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - All merger-related proposals were approved at the Annual Meeting of Stockholders, indicating progress in the merger process.
Why It Matters - Approval of merger-related proposals can lead to increased synergies, cost savings, and market expansion, potentially boosting stock value and investor confidence.
Wed, 10 Aug 2022
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Roche's Morpheus Platform will include a new study aimed at accelerating the development of innovative cancer immunotherapy combinations.
Why It Matters - Roche's Morpheus Platform could accelerate cancer treatment advancements, potentially increasing market share and revenue, positively impacting stock performance.
Thu, 04 Aug 2022
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Caladrius Biosciences, Inc. (NASDAQ: CLBS) held its Q2 2022 financial results conference call on August 4, 2022, featuring executives discussing company performance and updates.
Why It Matters - Caladrius Biosciences' Q2 results and business update may impact stock performance, signaling financial health and strategic direction, influencing investor sentiment and decisions.
Thu, 04 Aug 2022
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The merger with Cend Therapeutics is set to close in Q3 2022, pending stockholder approval, leading to the creation of Lisata Therapeutics.
Why It Matters - The merger's progress indicates potential growth and strategic advantages for Lisata Therapeutics, impacting investor confidence and future valuation. Stockholder approval is crucial for finalization.
Wed, 03 Aug 2022
Sentiment - NEUTRAL
Source - Business Wire
Summary - Former Louisiana Attorney General Charles C. Foti, Jr. and Kahn Swick & Foti, LLC are investigating Caladrius Biosciences' merger with Cend Therapeutics, focusing on potential undervaluation for shareholders.
Why It Matters - The investigation into Caladrius's merger raises concerns about valuation and shareholder equity, potentially impacting stock prices and investor confidence in the company's future.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
